Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3/12/25 19:05 | 3/10/25 | CRSP | Health | BioPrd | Biological Products, (No Diag | Kulkarni Samarth | MA | DO | CEO | 6 | M.dm | 2,859 | 26.82 | 0 | 107 | 61 | 281 | D | ||||||||||||||
3/12/25 19:05 | 3/11/25 | CRSP | Health | BioPrd | Biological Products, (No Diag | Kulkarni Samarth | MA | DO | CEO | 6 | S.dm | -2,859 | 26.82 | 0 | -107 | 281 | D | |||||||||||||||
3/12/25 19:05 | 3/10/25 | CRSP | Health | BioPrd | Biological Products, (No Diag | Kasinger James R. | MA | O | GC,Secre | 4 | M.dm | 789 | 16.75 | 0 | 47 | 149 | 79 | D | ||||||||||||||
3/12/25 19:05 | 3/11/25 | CRSP | Health | BioPrd | Biological Products, (No Diag | Kasinger James R. | MA | O | GC,Secre | 4 | S.dm | -789 | 16.75 | 0 | -47 | 79 | D | |||||||||||||||
3/12/25 19:05 | 3/10/25 | CRSP | Health | BioPrd | Biological Products, (No Diag | Bruno Julianne | MA | O | COO | 4 | M.dm | 77 | 14.72 | 0 | 5 | 50 | 16 | D | ||||||||||||||
3/12/25 19:05 | 3/11/25 | CRSP | Health | BioPrd | Biological Products, (No Diag | Bruno Julianne | MA | O | COO | 4 | S.dm | -77 | 14.72 | 0 | -5 | 16 | D | |||||||||||||||
2/28/25 17:35 | 2/26/25 | CRSP | Health | BioPrd | Biological Products, (No Diag | Greene John | MA | D | 1 | P | 314 | 44.85 | 0 | 7 | 7 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |